Skip to main content
. 2019 Nov 25;16(2):169–176. doi: 10.1007/s13181-019-00740-z

Fig. 2.

Fig. 2

Twenty-four-hour urinary excretion of the parent drug, APAP (panel a), and its non-oxidative APAP metabolites (APAP-Gluc, panel b; and APAP-Sulf, panel c) as percent of the ingested APAP dose for 5 subjects in each of the 2 treatment groups. Dotted lines connect individual subjects to illustrate individual changes.